Active Supportive Care and Symptom Management Grants
PI Name |
Organization - Company | Title | FOA |
|---|---|---|---|
| Basch, Ethan M. | Univ Of North Carolina Chapel Hill | Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability | RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
| Gray, Robert J | Dana-Farber Cancer Inst | Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) | RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
| Hui, David | University Of Tx Md Anderson Can Ctr | A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients | PA-16-160: NIH Research Project Grant |
| Hui, David | University Of Tx Md Anderson Can Ctr | Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients | PAR-18-559: Cancer Prevention and Control Clinical Trials Grant Program |
| Krause, Diane S | Yale University | "Exploration of Human Parathyroid Cellular Organization and Function" | PAR-19-356: NCI Clinical and Translational Exploratory/Developmental Studies |
| Miaskowski, Christine A. | University Of California, San Francisco | Impact of Hearing Loss and Tinnitus in Cancer Survivors | PA-16-160: NIH Research Project Grant |
| Mohile, Supriya G | University Of Rochester | Understanding Treatment Tolerability in Older Patients with Cancer | RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
| Rogatko, Andre | Cedars-Sinai Medical Center | Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials | RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
| Sanft, Tara B | Yale University | A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence | PAR-16-122: Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival |
| Sherman, Larry S | Oregon Health & Science University | Hyaluron as a regulator of chemotherapy-induced changes in neurogenesis | PA-16-258: Mechanisms of Cancer and Treatment-related Symptoms and Toxicities |
| Sorror, Mohamed | Fred Hutchinson Cancer Center | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | PA-17-018: Palliative Care Needs of Individuals with Advanced Rare Diseases and Their Family Caregivers |
| Stover, Daniel G. | Ohio State University | Video Intervention to Address Pre-Test Patient Education for Tumor Genomic Testing | PAR-19-356: NCI Clinical and Translational Exploratory/Developmental Studies |
| Strati, Paolo | University Of Tx Md Anderson Can Ctr | Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma | PAR-19-356: NCI Clinical and Translational Exploratory/Developmental Studies |